Cargando…

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy

BACKGROUND: Metabolic and energy disorders are considered central to the etiology of diabetic cardiomyopathy (DCM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) can effectively reduce the risk of cardiovascular death and heart failure in patients with DCM. However, the underlying mechanism has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xi, Yangbo, Chen, Dongping, Dong, Zhihui, Zhang, Jinhua, Lam, Hingcheung, He, Jiading, Du, Keyi, Chen, Can, Guo, Jun, Xiao, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579694/ https://www.ncbi.nlm.nih.gov/pubmed/36277768 http://dx.doi.org/10.3389/fcvm.2022.999254

Ejemplares similares

RNA Sequencing of Cardiac in a Rat Model Uncovers Potential Target LncRNA of Diabetic Cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: He, Jiading, et al.
Publicado: (2023)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Curcumin attenuates inflammation of Macrophage-derived foam cells treated with Poly-L-lactic acid degradation via PPARγ signaling pathway
por: Chen, Dongping, et al.
Publicado: (2022)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022)

Relevance of Multi-Omics Studies in Cardiovascular Diseases
por: Leon-Mimila, Paola, et al.
Publicado: (2019)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Multi-omics integration to identify the genetic expression and protein signature of dilated and ischemic cardiomyopathy
por: Portokallidou, Konstantina, et al.
Publicado: (2023)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies
por: Topf, Albert, et al.
Publicado: (2021)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
por: Huang, Keming, et al.
Publicado: (2023)

SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhao, Zinan, et al.
Publicado: (2022)

Cardiovascular Effects and Benefits of Exercise
por: Nystoriak, Matthew A., et al.
Publicado: (2018)

The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy
por: Ricci, Fabrizio, et al.
Publicado: (2020)

Cardiovascular Imaging in Stress Cardiomyopathy (Takotsubo Syndrome)
por: Zghyer, Fawzi, et al.
Publicado: (2022)

Recent Progress in Cardiovascular Research Involving Single-Cell Omics Approaches
por: Dai, Zhehao, et al.
Publicado: (2021)

Selective Interventricular Septal Radiofrequency Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy: Who Can Benefit?
por: Liu, Qiang, et al.
Publicado: (2021)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Cardiovascular Imaging in Pregnancy: Valvulopathy, Hypertrophic Cardiomyopathy, and Aortopathy
por: Ismail, Haneen, et al.
Publicado: (2022)

Evidence for the Benefits of Melatonin in Cardiovascular Disease
por: Tobeiha, Mohammad, et al.
Publicado: (2022)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies
por: Muñoz-Córdova, Felipe, et al.
Publicado: (2021)

Editorial: New insights and future prospects of atrial cardiomyopathy
por: Li, Yan-Guang
Publicado: (2023)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
por: Capuano, Annalisa, et al.
Publicado: (2022)

Radiomics-Based Classification of Left Ventricular Non-compaction, Hypertrophic Cardiomyopathy, and Dilated Cardiomyopathy in Cardiovascular Magnetic Resonance
por: Izquierdo, Cristian, et al.
Publicado: (2021)

Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy
por: Echeverría, Luis E., et al.
Publicado: (2021)

Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy
por: Heidari-Bateni, Giv, et al.
Publicado: (2021)

Telemedicine: Benefits for Cardiovascular Patients in the COVID-19 Era
por: Ghilencea, Liviu-Nicolae, et al.
Publicado: (2022)

Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
por: McCormack, Terry, et al.
Publicado: (2016)

Insights Into Mechanism of the Naphthalene-Enhanced Biodegradation of Phenanthrene by Pseudomonas sp. SL-6 Based on Omics Analysis
por: Cao, Hao, et al.
Publicado: (2021)

Cardiovascular and diabetes research in Africa to benefit from Servier sponsorship
Publicado: (2010)

Do Changes in Innate Immunity Underlie the Cardiovascular Benefits of Exercise?
por: Chuong, Phillip, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Editorial: Insights in cardiovascular therapeutics 2022—cardiovascular innate immunity
por: Xu, Keman, et al.
Publicado: (2023)

Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study
por: Frundi, Devine S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5tq92vnssnvg0q6b38c5tqcn46